Enko Dietmar, Halwachs-Baumann Gabriele, Stolba Robert, Rössler Ortrun, Kriegshäuser Gernot
Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Steyr, Sierningerstraße 170, 4400, Steyr, Austria.
Institute of Pathology, General Hospital Steyr, Sierningerstraße 170, 4400, Steyr, Austria.
Ann Clin Microbiol Antimicrob. 2016 Aug 8;15(1):47. doi: 10.1186/s12941-016-0161-1.
A growing number of rapid Helicobacter pylori antibody tests are commercially available now, however, some of these tests are often used without sufficient evaluation. The aim of this study was to evaluate the performance of a commercially available rapid whole-blood immunoassay (gabControl(®) H. pylori; gabmed GmbH, Köln, Germany), for the qualitative detection of IgG antibodies against H. pylori with the (13)C-urea breath test ((13)C-UBT) serving as a reference method.
A total of 108 consecutive outpatients, who were referred for (13)C-UBT by general practitioners and specialists, were also tested for H. pylori infection by the gabControl(®) H. pylori immunoassay. The clinical performance of this rapid whole-blood test was evaluated by determining the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) compared to the (13)C-UBT. The agreement between the two tests was calculated using Cohen's Kappa (κ) with 95 % confidence intervals (CI).
The agreement between the gabControl(®) H. pylori assay and the (13)C-UBT was 0.62 [95 % confidence intervals (CIs) 0.47-0.76; P < 0.001]. With the (13)C-UBT serving as the non-invasive gold standard method of H. pylori diagnosis, the gabControl(®) H. pylori assay demonstrated a sensitivity and specificity of 91.4 and 76.7 %, respectively, with a PPV of 65.3 % and a NPV of 94.9 %. Seventeen (15.7 %) individuals with a positive H. pylori anamnesis showed a negative (13)C-UBT and were typed positive by the gabControl(®) H. pylori assay. Of these, 13 (76.5 %) and 3 individuals (17.6 %) had completed one and two eradication therapies, respectively.
The gabControl(®) H. pylori immunoassay is a rapid and easy to use first line screening tool for H. pylori IgG antibody detection in daily clinical practice. However, this assay should not be used for confirmation of the successful H. pylori eradication after antibiotic treatment.
目前市面上有越来越多的快速幽门螺杆菌抗体检测产品,然而,其中一些检测方法在使用时往往缺乏充分评估。本研究旨在评估一种市售的快速全血免疫分析法(gabControl®幽门螺杆菌检测试剂盒;德国科隆gabmed有限公司)检测幽门螺杆菌IgG抗体的性能,以碳-13尿素呼气试验(¹³C-UBT)作为参考方法。
共有108名连续的门诊患者,他们由全科医生和专科医生转诊来进行¹³C-UBT检测,同时也采用gabControl®幽门螺杆菌免疫分析法检测幽门螺杆菌感染情况。通过与¹³C-UBT比较,测定该快速全血检测的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV),以评估其临床性能。使用Cohen's Kappa(κ)系数及95%置信区间(CI)计算两种检测方法之间的一致性。
gabControl®幽门螺杆菌检测试剂盒与¹³C-UBT之间的一致性为0.62[95%置信区间(CI)0.47 - 0.76;P < 0.001]。以¹³C-UBT作为幽门螺杆菌诊断的非侵入性金标准方法,gabControl®幽门螺杆菌检测试剂盒的敏感性和特异性分别为91.4%和76.7%,PPV为65.3%,NPV为94.9%。17名(15.7%)有幽门螺杆菌感染既往史的个体¹³C-UBT检测结果为阴性,但gabControl®幽门螺杆菌检测试剂盒检测为阳性。其中,13名(76.5%)和3名个体(17.6%)分别完成过一次和两次根除治疗。
gabControl®幽门螺杆菌免疫分析法是日常临床实践中一种快速且易于使用的幽门螺杆菌IgG抗体检测一线筛查工具。然而,该检测方法不应被用于确认抗生素治疗后幽门螺杆菌的成功根除情况。